- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 24 March 2025
Submitting member has a registered interest.
-
Current Status:
Answer expected on 21 April 2025
To ask the Scottish Government what assessment it has made of the impact of the delay in implementing the Fracture Liaison Service audit on the ability to (a) evaluate gaps in osteoporosis care and (b) prevent avoidable fractures.
Answer
Answer expected on 21 April 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 19 March 2025
-
Current Status:
Taken in the Chamber on 27 March 2025
To ask the Scottish Government what its response is to reports of some teachers requesting self-defence classes due to the prevalence of violence in schools.
Answer
Taken in the Chamber on 27 March 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 26 February 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 11 March 2025
To ask the Scottish Government how many people in Scotland have (a) transfusion dependent thalassaemia and (b) sickle cell disease, also broken down by how many might be eligible for treatment with exagamglogene autotemcel, a gene-edited therapy manufactured in Scotland, if this was made available.
Answer
The Scottish Government does not hold data centrally on the numbers of people with transfusion-dependent thalassaemia or sickle cell disease.
The question of how many might be eligible for exagamglogene autotemcel treatment, if it were available, would be a matter for individual clinicians following all guidance on eligibility and any required testing to ascertain this.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 26 February 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 11 March 2025
To ask the Scottish Government, following the treatment, exagamglogene autotemcel, which is a gene-edited therapy manufactured in Scotland, being approved for use in England to treat (a) transfusion dependent thalassaemia and (b) sickle cell disease, what engagement it is having with the NHS and suppliers toward making this available in Scotland, also broken down by what date it will be made available to people eligible for it, if approved.
Answer
The Scottish Medicines Consortium (SMC) has received a submission through the Ultra-Orphan Pathway from the marketing authorisation holder, Vertex Pharmaceuticals, for exagamglogene autotemcel (Casgevy®) for the treatment of transfusion-dependent ß-thalassaemia in patients 12 years of age and older. A decision on whether Casgevy® is accepted on to the Ultra-Orphan Pathway for this indication will be published on the SMC website in due course.
The SMC has not yet received a submission from Vertex Pharmaceuticals for Casgevy® for the treatment of sickle cell disease (SCD). I refer the member to the answer to question S6W-34796 on 25 February 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 05 March 2025
-
Current Status:
Taken in the Chamber on 13 March 2025
To ask the Scottish Government whether it will provide an update on the progress with the cladding remediation programme.
Answer
Taken in the Chamber on 13 March 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 29 January 2025
-
Current Status:
Taken in the Chamber on 5 February 2025
To ask the Scottish Government what it is doing to support and grow the night-time economy in Glasgow.
Answer
Taken in the Chamber on 5 February 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 22 January 2025
-
Current Status:
Taken in the Chamber on 29 January 2025
To ask the Scottish Government whether it will provide an update on the replacement of HMP Barlinnie, including in relation to the delivery date and cost.
Answer
Taken in the Chamber on 29 January 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Thursday, 12 December 2024
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 6 January 2025
To ask the Scottish Government for which conditions policy will be developed as a result of the additional funding for long-term conditions outlined in its draft Budget 2025-26.
Answer
In addition to funding to support the expansion of access to diabetes technology already announced in the financial year 2024-2025, the draft Budget for 2025-2026 contains funding to support continued policy development for long term conditions including diabetes, respiratory conditions, chronic pain, neurological conditions, heart disease and out-of-hospital cardiac arrest.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 13 December 2024
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 23 December 2024
To ask the Scottish Government what its response is to reports that contracts with pharmacies in NHS Lothian to receive and replace used sharps bins for patients requiring to take injectable medicines have ended due to lack of funds.
Answer
The Scottish Government is aware that currently some individuals across NHS Lothian are experiencing difficulties disposing of their sharps waste.
While the provision of NHS pharmaceutical services is the responsibility of the Scottish Government, the responsibility for providing arrangements for individuals to safely dispose of prescribed needles and other associated sharps waste is the responsibility of local Health Boards. In NHS Lothian this is delivered by community pharmacies through a local enhanced service for prescribed medicines and sharps waste disposal.
The Scottish Government is in close contact with NHS Lothian, and the Board is actively working with their four Health and Social Care Partnerships and Community Pharmacy Lothian to address the situation.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 13 December 2024
Submitting member has a registered interest.
-
Current Status:
Answered by Neil Gray on 19 December 2024
To ask the Scottish Government what the recommended protocol is for (a) disposing of and (b) obtaining replacement sharps bins.
Answer
The supply of sharps boxes and management of their return is linked to prescribing practice and contract arrangements between the health board and its contractors. Therefore, specific arrangements in any health board area would require to be requested from the local health board or, for patients, their prescribing physician would advise as to arrangements.